C
Chris Parker
Researcher at Institute of Cancer Research
Publications - 479
Citations - 35757
Chris Parker is an academic researcher from Institute of Cancer Research. The author has contributed to research in topics: Prostate cancer & Radiation therapy. The author has an hindex of 79, co-authored 422 publications receiving 30260 citations. Previous affiliations of Chris Parker include The Royal Marsden NHS Foundation Trust & University of Toronto.
Papers
More filters
Journal ArticleDOI
Active surveillance in prostate cancer: patient selection and triggers for intervention.
TL;DR: How recent advances have influenced patient selection for active surveillance is considered, the range of different intervention triggers that have been proposed are reviewed and the role of transperineal template biopsies and multiparametric MRI is considered.
Journal ArticleDOI
3-year safety follow-up of radium-223 dichloride (Ra-223) in patients (Pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (Mets) from ALSYMPCA.
Chris Parker,Nicholas J. Vogelzang,A. Oliver Sartor,Robert E. Coleman,Fang Fang,Irene Skjorestad,Sten Nilsson +6 more
TL;DR: Final safety data including long-term follow-up safety 3 years after last pt’s first injection (inj) of Ra-223 is released, highlighting the need for continued safety monitoring of the α-emitter.
Journal ArticleDOI
Prostate Cancer Unit Initiative in Europe: A position paper by the European School of Oncology
Riccardo Valdagni,Hendrik Van Poppel,Michael Aitchison,Peter Albers,Dominik Berthold,Alberto Bossi,Maurizio Brausi,Louis Denis,Lawrence Drudge-Coates,Maria De Santis,Günther Feick,Chris Harrison,Karin Haustermans,Donal Hollywood,Morton Hoyer,Henk Hummel,Malcolm David Mason,Vincenzo Mirone,Stefan C. Müller,Chris Parker,Mahasti Saghatchian,Cora N. Sternberg,Bertrand Tombal,Erik van Muilekom,Maggie Watson,Simone Wesselmann,Thomas Wiegel,Tiziana Magnani,Alberto Costa +28 more
TL;DR: The relevant, feasible and applicable core criteria for defining PCUs in most European countries delivered by PCU Initiative in Europe Task Force are described.
Journal ArticleDOI
The Case Against the European Medicines Agency's Change to the Label for Radium-223 for the Treatment of Metastatic Castration-resistant Prostate Cancer.
Joe M. O'Sullivan,Daniel Heinrich,Nicholas D. James,Sten Nilsson,Piet Ost,Chris Parker,Bertrand Tombal +6 more
Journal ArticleDOI
Identification of new genetic risk factors for prostate cancer
Michelle Guy,Zsofia Kote-Jarai,Graham G. Giles,Graham G. Giles,Ali Amin Al Olama,Sarah Jugurnauth,Shani Mulholland,Daniel Leongamornlert,Stephen M. Edwards,Jonathan J. Morrison,Helen I. Field,Melissa C. Southey,Gianluca Severi,Gianluca Severi,Jenny L Donovan,Freddie C. Hamdy,David P. Dearnaley,David P. Dearnaley,Kenneth Muir,Charmaine Smith,Melisa Bagnato,Audrey Ardern-Jones,Amanda L. Hall,Amanda L. Hall,Lynne T. O'Brien,Beatrice N. Gehr-Swain,Beatrice N. Gehr-Swain,Rosemary A. Wilkinson,Angela Cox,Sarah J Lewis,Paul M. Brown,Sameer Jhavar,Malgorzata Tymrakiewicz,Artitaya Lophatananon,Sarah L Bryant,Alan Horwich,Alan Horwich,Robert Huddart,Robert Huddart,Vincent Khoo,Vincent Khoo,Chris Parker,Chris Parker,C. R. J. Woodhouse,Alan Thompson,Tim Christmas,Chris Ogden,Cyril Fisher,Charles Jameson,Colin Cooper,Dallas R. English,John L. Hopper,David E. Neal,David E. Neal,Douglas F. Easton,Rosalind A. Eeles,Rosalind A. Eeles +56 more
TL;DR: It is considered that marketing of tests to the public is premature, as PCa risk can not be evaluated fully at this stage and the appropriate screening protocols need to be developed.